Retatrutide's TRIUMPH-1 Phase 3 Data: 28.3% Weight Loss, a Pending NDA, and What It Means for Research Labs

Key takeaways

• Eli Lilly released Phase 3 TRIUMPH-1 topline data on 21 May 2026, showing retatrutide 12 mg achieved an average 28.3% body-weight reduction at 80 weeks and 30.3% at 104 weeks in a high-BMI sub-group.
• All three dose arms (4 mg, 9 mg, 12 mg) met primary and key secondary endpoints against placebo.
• Retatrutide remains unapproved by the FDA, EMA, or MHRA; a regulatory submission is expected in late 2026 at the earliest, with approval not anticipated before 2027.
• Unlike semaglutide or tirzepatide, retatrutide has no approved commercial form, no shortage exemption, and no legal compounding pathway in the US or UK.
• Research suppliers are already marketing retatrutide as a research-use-only compound; procurement teams should apply standard diligence criteria — third-party HPLC/MS verification, lot-matched CoA, GMP-sourced API — before placing orders.

What TRIUMPH-1 showed

On 21 May 2026, Eli Lilly announced positive topline results from TRIUMPH-1 (NCT05929066), a randomised, double-blind, placebo-controlled Phase 3 trial evaluating retatrutide in 2,339 adults with obesity or overweight and at least one weight-related comorbidity, but without type 2 diabetes.

Participants on the 12 mg dose lost an average of 70.3 lb — a 28.3% reduction from baseline — over 80 weeks. According to Lilly's investor release, 45.3% of those patients achieved ≥30% weight loss, a threshold long associated with bariatric surgery. In a pre-specified 104-week extension enrolling patients with baseline BMI ≥35, the 12 mg group reached an average 85 lb reduction, equal to 30.3% of starting body weight.

The 9 mg dose produced 25.9% average weight reduction at 80 weeks, and even the 4 mg arm — requiring only a single dose-escalation step — delivered 19.0% average weight reduction with a lower observed discontinuation rate due to adverse events than the higher doses, according to AJMC's coverage of the trial.

BioPharma Dive noted that the data suggest retatrutide will provide greater weight loss than Lilly's own sector-leading Zepbound (tirzepatide) and could set a new benchmark for Novo Nordisk's Wegovy as well as other obesity rivals including Roche, AstraZeneca, and Structure Therapeutics.

The mechanistic distinction

Retatrutide targets three metabolic pathways simultaneously — GLP-1, GIP, and glucagon receptors — making it a distinct class from both semaglutide (GLP-1 only) and tirzepatide (dual GIP/GLP-1). Yahoo Finance's trial coverage summarised this clearly: Lilly's current market leader Zepbound covers only the first two, and Novo Nordisk's Wegovy is limited to GLP-1 alone. The additional glucagon component is credited with driving deeper body-weight and cardiometabolic reductions, though it also introduces a higher gastrointestinal adverse-event burden at the top dose.

On tolerability, Lilly's press release reports nausea in 42.4% of 12 mg participants, diarrhoea in 32%, and constipation in 26.1%. Dysaesthesia — an abnormal sensory sensation — occurred in over 12% of the highest-dose arm, consistent with earlier Phase 2 results. The discontinuation rate due to adverse events at the 12 mg dose was 11.3%. These figures will bear comparison with full safety data to be presented at the 86th American Diabetes Association Scientific Sessions, where full TRIUMPH-1 results are expected alongside other TRIUMPH programme readouts.

Where the Phase 3 programme stands

TRIUMPH-1 is the first registrational obesity trial in the programme to report, but it is not the last. Pharmacy Times confirmed that TRIUMPH-2 (adults with obesity and type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) data are expected later in 2026. A TRIUMPH cardiovascular outcomes trial (TRIUMPH-CVOT) is also running, with a readout expected later this decade.

According to the Pharmaceutical Journal, a regulatory submission for retatrutide is anticipated in 2026 as the full data package matures, with approval not anticipated before 2027 at the earliest in both the US and UK. For context, the TRANSCEND-T2D-1 trial in type 2 diabetes — with topline data released in March 2026 — reported that participants on 12 mg retatrutide lost an average of 16.8% of their body weight at 40 weeks, supplementing the obesity dataset.

Lilly's retatrutide information page confirms the compound is currently being studied in Phase 3 across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD). An NDA filing in Q4 2026 or Q1 2027 is widely considered the most plausible scenario.

Regulatory status: what research labs must understand

The TRIUMPH-1 result will generate immediate and significant interest in retatrutide as a research-use-only compound. Procurement teams at UK laboratories should be clear on the following points before any acquisition decision.

No approved form exists anywhere. As of May 2026, retatrutide has not been approved by the FDA, EMA, or any other major regulator. It remains an investigational compound exclusively available to participants in Lilly's clinical trials through licensed clinical sites.

Compounding is explicitly prohibited in the US. GLP3 Planner's regulatory summary notes that retatrutide fails all three criteria for 503A and 503B compounding: there is no USP/NF monograph, it is not an approved drug component, and it does not appear on any shortage list. Unlike semaglutide or tirzepatide — which had shortage-derived compounding windows — retatrutide has never had an approved commercial form, so no shortage exemption ever applied.

In the UK, the position mirrors the US. Retatrutide has no MHRA marketing authorisation and no European Medicines Agency approval. Material sold as retatrutide in the UK for research use is subject to the same MHRA framework that governs other research-use-only peptides: lawful to supply without therapeutic claims, but with no clinical use permitted.

Gray-market product exists and carries significant quality risk. Research peptide vendors are already listing retatrutide following the TRIUMPH-1 announcement. Procurement professionals should note that the FDA has issued warning letters in connection with illegally marketed retatrutide products, and that any such material sourced outside a clinical trial carries unverifiable quality, purity, and identity risks. Standard due diligence applies: third-party HPLC purity testing, mass-spectrometry identity confirmation, lot-matched Certificate of Analysis, and GMP-sourced API documentation should be minimum requirements.

What the data means for the broader research landscape

TRIUMPH-1 establishes retatrutide as the most efficacious single injectable agent in the GLP-1/incretin class by raw weight-loss outcome, at least as measured in Phase 3 data released to date. The 30.3% result at 104 weeks in the high-BMI extension sub-group is a figure that brings injectable pharmacotherapy within the range historically associated with bariatric surgery.

For UK research labs, the practical consequence is an increase in researcher interest in triple-agonist peptide biology — particularly the additive role of glucagon receptor activation on adipose mobilisation, hepatic glucose output, and energy expenditure. Several academic groups have been tracking the TRIUMPH programme precisely because retatrutide's glucagon-agonist component offers a mechanistic lever not available in approved dual-agonist compounds. Those projects can proceed with research-grade material acquired through compliant suppliers; what they cannot do, under UK or US law, is repurpose that material for clinical or therapeutic use outside a licensed trial.

The TRIUMPH-1 data also sharpens procurement planning: with an NDA submission expected before year-end 2026 and approval on the 2027 horizon, demand for reference standard material and validated research-grade retatrutide will likely increase substantially in the coming twelve months.